Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

B. E. Sands*, W. J. Sandborn, R. Panaccione, C. D. O'Brien, H. Zhang, J. Johanns, O. J. Adedokun, K. Li, L. Peyrin-Biroulet, G. Van Assche, S. Danese, S. Targan, M. T. Abreu, T. Hisamatsu, P. Szapary, C. Marano, Marieke Pierik, UNIFI Study Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1201-1214
Number of pages14
JournalNew England Journal of Medicine
Volume381
Issue number13
DOIs
Publication statusPublished - 26 Sep 2019

Keywords

  • ACTIVITY INDEXES
  • INFLIXIMAB
  • INFECTIONS
  • EFFICACY

Cite this

Sands, B. E., Sandborn, W. J., Panaccione, R., O'Brien, C. D., Zhang, H., Johanns, J., Adedokun, O. J., Li, K., Peyrin-Biroulet, L., Van Assche, G., Danese, S., Targan, S., Abreu, M. T., Hisamatsu, T., Szapary, P., Marano, C., Pierik, M., & UNIFI Study Grp (2019). Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 381(13), 1201-1214. https://doi.org/10.1056/NEJMoa1900750